12:14 PM EST, 01/17/2025 (MT Newswires) -- Bausch Health ( BHC ) and its Salix Pharmaceuticals unit acknowledged Friday the inclusion of Xifaxan 550 milligram tablets in the second round of price negotiations under the Inflation Reduction Act.

Bausch Health ( BHC ) and Salix said they look forward to the discussions with the US Department of Health and Human Services' Centers for Medicare and Medicaid Services, or CMS.

In a separate statement, CMS said negotiations will be conducted this year and any negotiated prices will take effect in 2027.

Drug companies with a selected drug for price negotiations have until Feb. 28 to decide on their participation in the talks, according to the statement.

Price: 7.63, Change: -0.02, Percent Change: -0.26